<DOC>
	<DOCNO>NCT00082511</DOCNO>
	<brief_summary>Open label safety efficacy follow-up .</brief_summary>
	<brief_title>GL701 ( Prestara™ ) Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids</brief_title>
	<detailed_description>This randomize , multi-center , open-label , parallel-group , trial prasterone 200 100 mg/day 12 month woman lupus receive glucocorticoid therapy complete earlier 6-month randomized , placebo-controlled study ( NCT00053560 . Bone Mineral Density assessment perform baseline month 6 12 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Patient complete full 6 month treatment period study drug previous Genelabs ' clinical study GL0201 . Concomitant treatment prednisone ( equivalent ) dose ≥ 5mg/day . Patient read sign Informed Consent Form . If patient fluent English , Informed Consent must sign native language . Patient serious study drug relate adverse reaction time previous GL0201 study . Any condition Investigator 's Sponsor 's opinion sufficient prevent adequate compliance study likely confuse followup evaluation ( e.g. , alcoholism , drug addiction , acute withdrawal chemical dependency , psychiatric disease ) . MEDICATIONS PROHIBITED AT ANY TIME DURING THE STUDY Calcitonin Bisphosphonates Fluoride pharmacologic dose Strontium pharmacologic dose Estrogenic steroid ( except oral contraceptive ) Selective Estrogen Receptor Modulator ( raloxifene ) Parathyroid hormone Any androgen , include prescription nutritional supplement DHEA , study drug Additional Calcium supplement prescribe part study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Systemic Lupus Erythematosus</keyword>
	<keyword>SLE</keyword>
	<keyword>Bone Loss</keyword>
	<keyword>DHEA</keyword>
</DOC>